Articles with public access mandates - Peter SeverLearn more
Not available anywhere: 5
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
CT Trialists
The Lancet 371 (9607), 117-125, 2008
Mandates: British Heart Foundation
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset …
MS Sabatine, LA Leiter, SD Wiviott, RP Giugliano, P Deedwania, ...
The lancet Diabetes & endocrinology 5 (12), 941-950, 2017
Mandates: National Institute for Health Research, UK
First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study
JE Davies, CH Manisty, R Petraco, AJ Barron, B Unsworth, J Mayet, ...
International journal of cardiology 162 (3), 189-192, 2013
Mandates: British Heart Foundation
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
MS Sabatine, RP Giugliano, A Keech, N Honarpour, H Wang, T Liu, ...
American heart journal 173, 94-101, 2016
Mandates: National Institute for Health Research, UK
Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials
BPLT Trialists’Collaboration, A Ying, H Arima, S Czernichow, ...
Lancet 385 (9971), 867-74, 2015
Mandates: Australian Research Council, National Health and Medical Research Council …
Available somewhere: 130
Heart disease and stroke statistics—2017 update: a report from the American Heart Association
EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ...
circulation 135 (10), e146-e603, 2017
Mandates: US National Institutes of Health, American Heart Association
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ...
New England journal of medicine 376 (18), 1713-1722, 2017
Mandates: UK Medical Research Council, National Institute for Health Research, UK
Genetic studies of body mass index yield new insights for obesity biology
AE Locke, B Kahali, SI Berndt, AE Justice, TH Pers, FR Day, C Powell, ...
Nature 518 (7538), 197-206, 2015
Mandates: US National Institutes of Health, British Heart Foundation, Cancer Research …
Treatment of hypertension in patients 80 years of age or older
NS Beckett, R Peters, AE Fletcher, JA Staessen, L Liu, D Dumitrascu, ...
New England Journal of Medicine 358 (18), 1887-1898, 2008
Mandates: British Heart Foundation
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
CT Trialists
The Lancet 376 (9753), 1670-1681, 2010
Mandates: British Heart Foundation, Cancer Research UK
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
PM Rothwell, SC Howard, E Dolan, E O'Brien, JE Dobson, B Dahlöf, ...
The Lancet 375 (9718), 895-905, 2010
Mandates: British Heart Foundation
Defining the role of common variation in the genomic and biological architecture of adult human height
AR Wood, T Esko, J Yang, S Vedantam, TH Pers, S Gustafsson, AY Chu, ...
Nature genetics 46 (11), 1173-1186, 2014
Mandates: US National Institutes of Health, British Heart Foundation, UK Medical …
Interpretation of the evidence for the efficacy and safety of statin therapy
R Collins, C Reith, J Emberson, J Armitage, C Baigent, L Blackwell, ...
The Lancet 388 (10059), 2532-2561, 2016
Mandates: National Health and Medical Research Council, Australia, British Heart …
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits
E Evangelou, HR Warren, D Mosen-Ansorena, B Mifsud, R Pazoki, H Gao, ...
Nature genetics 50 (10), 1412-1425, 2018
Mandates: Swiss National Science Foundation, US National Institutes of Health, US …
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
B Williams, TM MacDonald, S Morant, DJ Webb, P Sever, G McInnes, ...
The Lancet 386 (10008), 2059-2068, 2015
Mandates: British Heart Foundation, UK Medical Research Council, National Institute …
Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke
PM Rothwell, SC Howard, E Dolan, E O'Brien, JE Dobson, B Dahlöf, ...
The Lancet Neurology 9 (5), 469-480, 2010
Mandates: British Heart Foundation
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
DI Swerdlow, D Preiss, KB Kuchenbaecker, MV Holmes, JEL Engmann, ...
The Lancet 385 (9965), 351-361, 2015
Mandates: US National Institutes of Health, John D. and Catherine T. MacArthur …
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
JL Mega, NO Stitziel, JG Smith, DI Chasman, MJ Caulfield, JJ Devlin, ...
The Lancet 385 (9984), 2264-2271, 2015
Mandates: US National Institutes of Health, Swedish Research Council, UK Medical …
Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular …
MP Bonaca, P Nault, RP Giugliano, AC Keech, AL Pineda, E Kanevsky, ...
Circulation 137 (4), 338-350, 2018
Mandates: National Institute for Health Research, UK
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
J Armitage, C Baigent, E Barnes, DJ Betteridge, L Blackwell, M Blazing, ...
The Lancet 393 (10170), 407-415, 2019
Mandates: National Health and Medical Research Council, Australia, British Heart …
Publication and funding information is determined automatically by a computer program